Drug Approval | December 10, 2021
China approves Brii Bio’s antibody combination to neutralise Covid-19
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
The platform’s technology works as a compression algorithm for molecular testing
The Uteshiya facility, licensed by Healthium, will exclusively manufacture Healthium’s arthroscopy portfolio, including patented products in India and U.S.
The license agreement grants Dr. Reddy's the exclusive rights to commercialize the proposed biosimilar in select countries in Latin America and Southeast Asia
An MoU was signed between B Medical Systems and Gujarat government recently
The company plans to expand their capacity to meet the needs of pharma and biotech industries
SPARC will be eligible to receive an upfront payment, milestone payments and royalty on sales, in addition to 10% equity in Visiox
This is the fourth facility from the company to receive this registration
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
As part of the out-licensing deal with Tabuk, Biocon will develop and manufacture the products, and Tabuk will commercialise them
Subscribe To Our Newsletter & Stay Updated
